biolongevity labs retatrutide GLP3-R (Retatrutide) · Awaken Bio GLP-3(10185) - BioLongevity Labs

Foundayo additionally lists hair loss, which is common across the class and generally temporary

Your provider should monitor you regularly, but long-term treatment is considered safe and effective for weight management and metabolic health when medically appropriate

How Retatrutide Compares: GLP-1 Agonist Class Overview To contextualise Retatrutide's research profile, the following table summarises key distinctions across the three major GLP-1 class compounds studied in Australian research contexts: No direct head-to-head trial between all three compounds has been published

But the tirzepatide shortage was declared resolved in December 2024, and the semaglutide shortage was declared resolved in February 2025

If you notice swelling, fatigue, or changes in urination, its important to contact your provider

Three Times Weekly Titration (Mon/Wed/Fri) A step beyond twice-weekly with ~35% peak reduction